Final Results, Notice of AGM and Related Party Transaction
The Board of 4basebio plc is pleased to report the results for the financial year ended 31 December 2022.
The annual report and accounts together with a notice of the Company’s annual general meeting, which is to be held on 14 June 2023 at 9:00am in the offices of 4basebio plc are expected to be uploaded to the Company's website and posted to shareholders shortly.
The annual general meeting will be followed by a presentation from the Company through the Investor Meet Company platform on 16 June 2023 at 10am. Investors can sign up to Investor Meet Company for free and register interest here: https://www.investormeetcompany.com/4basebio-plc/register-investor.
The Company further advises that, on 10 May 2023, it amended the terms of its loan facility with 2Invest AG, a significant shareholder, which it entered into on 2 November 2020. Further details of the related party transaction are included below.
Highlights
First commercial revenues from DNA
First commercial revenues from Hermes™ non-viral vectors
Clean rooms for manufacture of GMP DNA commissioned
Six novel patent filings between January 2022 and February 2023
Continued growth with headcount increasing to 61 staff from 33 at the beginning of the year
Overview
4basebio plc is a Cambridge UK based AIM-quoted holding and service company for the 4basebio group of companies (“the Group”), which includes manufacturing and research and development subsidiaries across Cambridge, UK and Madrid, Spain.
4basebio is engaged in the research and development, manufacture and commercialisation of synthetic DNA and RNA products and targeted non-viral vector solutions. With its first revenues from these activities during 2022, the Group is now focussed on the scaling of its commercial activities across a range of gene therapy and vaccine applications, with a particular focus on mRNA and AAV markets.
The Group is able to offer its customers application specific solutions; it also continues to invest in research and development activities to further develop its technology platforms and expand its product offering.
Dr Heikki Lanckriet, CEO and CSO for 4basebio, said: “2022 has been a very exciting year for 4basebio, with the first commercial revenues from its synthetic DNA and Hermes™ platforms, completion of its manufacturing clean rooms, filing of fresh intellectual property and the overall growth is size and capabilities of the group. The group will continue to develop its platforms and is now also focussed on its commercial development with increasing revenue a key objective.”